ASCO: Bristol Myers' KRAS confirmatory data avoid Amgen's flaws but leave FDA prospect unclear

After Amgen’s KRAS confirmatory trial results were rejected by the FDA as uninterpretable, Bristol Myers Squibb has provided details of its rival study, which, even though the New Jersey pharma says it does not share the same design problems, leaves questions open for the regulatory outlook with the FDA.